Share on StockTwits

Aratana Therapeutics (NASDAQ:PETX) Insider Julia A. Stephanus unloaded 8,000 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $13.90, for a total transaction of $111,200.00. Following the completion of the transaction, the insider now directly owns 121,967 shares in the company, valued at approximately $1,695,341. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Aratana Therapeutics (NASDAQ:PETX) traded up 4.25% during mid-day trading on Monday, hitting $14.72. The stock had a trading volume of 213,407 shares. Aratana Therapeutics has a 1-year low of $6.56 and a 1-year high of $29.32. The stock has a 50-day moving average of $13.35 and a 200-day moving average of $17.41. The company’s market cap is $423.3 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.09 million. The company’s revenue for the quarter was up NaN% on a year-over-year basis. Analysts expect that Aratana Therapeutics will post $-1.51 EPS for the current fiscal year.

PETX has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Friday, June 6th. They now have a $23.00 price target on the stock, down previously from $25.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Wednesday, May 14th. They now have a $22.00 price target on the stock, down previously from $30.00. Finally, analysts at Zacks downgraded shares of Aratana Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, April 14th. They now have a $18.40 price target on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $28.40.

Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.